In the fast-paced world of health technology, DiaMonTech has been making waves throughout 2023, securing prestigious awards and recognition for its groundbreaking contributions to the field.

DiaMonTech receives recognition as the most innovative start-up in the field of "Nutrition, Metabolic and Intestinal Health" in this prestigious competition and secures first place.

The jury, invited by Navispace, recognized DiaMonTech's level of innovation, go-to-market strategy, commercial viability and sustainability.

Advancements in DiaMonTech's D-Pocket non-invasive blood glucose monitoring device with insights from DiaMonTech's CEO, Thorsten Lubinski, and COO, Sergius Janik, on the dual strategy for the device's introduction in Europe and the USA.

Berlin-based health tech company DiaMonTech has successfully closed a financing round, raising further millions with the Berlin based Moll Family GmbH in the lead.This investment will be instrumental in advancing their pioneering non-invasive glucose monitoring technology.

What exactly is the ground-breaking technology for non-invasive measurement of blood glucose levels? Prof. Dr. Werner Mäntele, CSO of DiaMonTech, explains in an interview with Dr. Olaf Gaus how the innovative infrared laser technology was developed and the advantages of 'measuring without a prick'.

This recognition underscores the company's commitment to developing groundbreaking solutions in healthcare.

Supported by Unorthodox Ventures, DiaMonTech's investor on site in Austin, DiaMonTech presented itself to international industry experts.

DiaMonTech's nomination as a finalist in The Europas Awards in the HealthTech category emphasizes our company's mission to improve everyday life with diabetes.

DiaMonTech, an award-winning medical technology start-up pioneering non-invasive blood glucose measurements, today announced a $5 million investment round, bringing its total funding to over $20 million. Adding Samsung Ventures and a global medical technology company as strategic partners reaffirms DiaMonTech’s ambition to revolutionize non-invasive diabetes management.

DiaMonTech is proud to announce the official QMS certification for  the design and development of non-invasive glucose monitoring devices from the notified body BerlinCert (ISO 13485:2016).

‍

‍

In the last weeks Forbes and Axios published two articles discussing the future of diabetes care with DiaMonTech.

‍

HanseMerkur, one of the largest private health insurance companies in Germany, and DiaMonTech AG, a medical technology company from Berlin, are planning a strategic cooperation to establish new processes in the treatment and early detection of diabetes by means of innovative care products.

DiaMonTech AG has completed another important step for the market approval of its technology in the US.

‍

The results of the study confirm the accuracy and precision of DiaMonTech's patented diagnostic technology.

Within the clinical study, the blood glucose of 100 volunteers was measured with the laser-based, non-invasive technology and compared in parallel with an invasive reference method. The non-invasive method of DiaMonTech achieved measurement results with a mean absolute relative deviation of only 11.1% and is therefore on an accuracy level with (minimal-)invasive devices already on the market.

‍

DiaMonTech AG has received a financing of about 1.2 million Euro from Investitionsbank Berlin (IBB).

DiaMonTech GmbH, a start-up specializing in non-invasive blood glucose measurement methods, has successfully completed its second financing round. In total, the company will receive around 5 million euros from old and new investors. The IBB Beteiligungsgesellschaft from Berlin, the Japanese electronics group Macnica and the Chinese venture capitalist Jindong Capital are the largest investors. DiaMonTech intends to use the money to advance...

DiaMonTech GmbH, a start-up company specializing in non-invasive blood glucose measurement methods, took part in the "Innovation trifft Politik" forum. At the series of events, which took place at the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), the company introduced itself to Federal Secretary of Health Jens Spahn, among others. The aim of the conference was to...

DiaMonTech GmbH, a start-up company specializing in non-invasive blood glucose measurement methods, was awarded the "Start me up!" prize by the business magazine BILANZ. A total of 243 start-ups participated in the 100,000 euros competition. The 14-member jury was convinced by the innovative and patented method for non-invasive measurement of...

DiaMonTech GmbH, a young and innovative medical technology company based in Berlin, published remarkable results of a clinical study, confirming the accuracy of its non-invasive blood glucose-monitoring technology. In the clinical study, the blood glucose of 100 volunteers was measured using DiaMonTech's laser-based, non-invasive technology and compared to a clinically established invasive reference measurement method. The non-invasive method achieved measurement results with a mean error of only 11 percent, which is otherwise only achieved with (minimally-) invasive devices. The convincing results confirm DiaMonTech's plans to launch a product for diabetics for the non-invasive measurement of blood glucose on the market as early as next year.

"The successful completion of the clinical 'Study 100' is a...

DiaMonTech GmbH, a young and innovative medical technology company has been nominated by EIT Digital, a leading European player in innovation and entrepreneurial education, as a finalist in its pan-European competition EIT Digital Challenge 2019. The competition focuses on startups in growth stage, so called scaleups, with deep tech products that leverage sophisticated, hard-to-reproduce technologies fueling the digital transformation.

"After winning the 'Start me up!' founder prize by BILANZ magazine in 2017, this is already the second renowned competition in which we have reached the final. In a field of nearly 300 participating start-ups, this is already a great...

DiaMonTech GmbH, a young medical technology company, has received the CE certification for its first medical product "DMT Base". The device enables non-invasive blood glucose measurement using laser-based technology. The certification confirms that the patented technology meets the high safety and performance standards for medical devices required for market approval. The label is valid for all...

DiaMonTech GmbH, a young and innovative medical technology company, has successfully completed its Series A financing round. The company will receive a total of more than 7 million euros. The lead investor for this growth financing is Bioventure, an investor specialized in biotech and life science. In addition, DiaMonTech has gained two family offices as new investors. Existing shareholders - such as IBB Beteiligungsgesellschaft via its fund "VC Fonds Technologie Berlin" - also participated in the financing round.
DiaMonTech's goal is to provide diabetes patients worldwide with a groundbreaking technology for...